| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fca91f0c4fa1abffc893daab61983c2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_483c6dc15ea7986359f280f17a2af1c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_198da85b667991df5016f48761ea53ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebfaa03b81fa833b75873256ced49964
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8925b769d645f9ff06af9f4b189f6a99 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 |
| filingDate |
2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_656dea8284906fa95e97e9867e2ba6ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5db8454d4b8921c49f917a054041779
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b8f32d731635ec7820eca140d75daa4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13fd76c158f7b2f9d37fae170d5667d1 |
| publicationDate |
2007-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006131790-A3 |
| titleOfInvention |
Oral ribavirin pharmaceutical composition |
| abstract |
The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using thèse oral compositions. One of the main problems considered in the present invention, is to enhance the efficiency of anti-viral treatments, especially against Hepatitis C by means of ribavirin, for example in combination with interferon. The oral ribavirin antiviral composition according to the invention increases the bio-absorption time of ribavirin, and thus improves the treatment of the patients. Said composition comprises at least one modified release form of ribavirin which bio-absorption time BAT is greater than the bio-absorption time BAT* of a reference* immediate release form of ribavirin administered at the same dose; BAT being preferably comprised between 2 and 15 hours and more preferably between 4 and 12 hours. Said composition is a reservoir type form or a matricial type form. Said composition is a gastric retentive System or a multiparticulate form. |
| priorityDate |
2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |